The application and versatility of medical imaging modalities are continuing to grow in significance as the population ages and healthcare costs rise. Examinations that can facilitate earlier disease diagnosis and the most appropriate treatment are in order. This bodes well for contrast media markets.

Since our last round-up of the contrast media market, the economic environment in the world has changed. Although the recession may have caused hospitals, physician offices and other institutions to delay or cancel the purchase of imaging equipment, it has not had a significant negative impact on the use of contrast agents with the equipment already on hand. Specifically, annual growth for medical contrast media during the next five years appears to be strong, despite the recession slowing capital equipment purchases. Imaging exams are still needed for many diagnoses, and contrast enhancement facilitates diagnosis in many cases. Expects growth ranges to remain high.

This comprehensive study of the world market for contrast agents builds on the previous modality-focused reports of medical imaging market reports. Coverage includes:

• World and regional revenue forecasts for contrast agents and radiopharmaceuticals by modality through 2012. (X-Ray, CT, Ultrasound, MRI, PET, SPECT)

• Market share of the major contrast agent supplers

• Procedure volumes by modality and region

• Estimates of the portion of procedures in each modality using contrast enhancement

• Contrast-enhancement products in development

The report also discusses technical developments and emerging application trends such as therapeutic monitoring, whole body screening, and guided therapeutic interventions, and how contrast agents are helping to expand imaging’s role in basic research and drug discovery/development. Specific advances in contrast agent-enabled diagnostics for mammography, Alzheimer’s, and other indications are also reviewed.

The report concludes with profiles of top suppliers and developers including:

• Acusphere Inc.

• Alseres Pharmaceuticals Inc.

• Amag Pharmaceuticals Inc.

• Aposense Ltd.

• Avid Radiopharmaceuticals Inc.

• Bayer Schering Pharma

• Bracco SpA

• 5.10 Cell Point

• Covidien Ltd.

• Daiichi Pharmaceutical Co. Ltd.

• Dendritic NanoTechnologies Inc.

• Draximage

• Endocyte Inc.

• Eusa Pharma

• GE Healthcare

• Guerbet Group

• Hovione FarmaCiencia SA

• Imcor Pharmaceutical Co.

• Immunomedics Inc.

• Insight Agents GmbH

• King Pharmaceuticals Inc.

• Luna nanoWorks

• Macrocyclics

• MDS Nordion

• NanoScan Imaging

• Palatin Technologies Inc.

• Pharmacyclics

• Point Biomedical Corp.

• Starpharma Holdings Ltd.

• VisEn Medical Inc.

 

 

1.0 EXECUTIVE SUMMARY

1.1 The Contrast Revolution

1.2 X-Ray and CT

1.3 Ultrasound

1.4 MRI

1.5 Radiopharmaceuticals

1.6 World Market Summary

1.6.1 Market Drivers and Trends

1.6.2 Market Challenges

1.6.2.1 Generics

1.6.3 World Market Growth Analysis

1.7 Methodology
 

2.0 INTRODUCTION

2.1 Harnessing Science to Optimize Outcomes

2.2 History and Evolution

2.3 Key Markets

2.3.1 X-Ray and CT

2.3.2 Ultrasound

2.3.2.1 Microbubbles

2.3.3 MRI

2.3.3.1 Novel Agents

2.3.4 Nuclear Medicine

2.3.4.1 Diagnostics

2.3.4.2 Sourcing Issues

2.3.4.3 PET

2.3.4.3.1 New Applications

2.3.4.4 SPECT

2.3.4.5 Gamma Cameras

2.4 Ionic and Non-Ionic Contrast

2.5 Reimbursement and Other Concerns

2.5.1 Volume Determination

2.5.2 Safety

2.5.3 Combination Technology
 

3.0 PROMISING DEVELOPMENTS

3.1 Detecting Prostate Cancer

3.2 Assessing Heart Risk

3.3 Breast Chemo Outcome

3.4 Software Enhancement

3.5 Four in One

3.6 Photoacoustic Tomography

3.7 Carbon Do

3.8 Nanomagnets

3.9 Kidney Damage

3.10 Angiograph

3.11 Iodinated Contras

3.12 Children

3.13 Dynamic Contrast-Enhanced MRI

3.14 Preclinica

3.15 Nanocolloid
 

4.0 MARKET

4.1 Market Drivers

4.1.1 Targeted Imaging

4.1.2 Increasing Specificity

4.1.3 Aging Population

4.2 Utilization

4.2.1 Procedures

4.3 Outlook for Contrast Media

4.3.1 Market Forecast

4.4 Outlook for Molecular Imaging Agents

4.4.1 Market Forecast

 

5.0 CORPORATE PROFILES

Acusphere Inc.

Alseres Pharmaceuticals Inc.

Amag Pharmaceuticals Inc.

Aposense Ltd.

Avid Radiopharmaceuticals Inc.

Bayer Schering Pharma

Bracco SpA

5.10 Cell>Point

Covidien Ltd.

Daiichi Pharmaceutical Co. Ltd.

Dendritic NanoTechnologies Inc.

Draximage

Endocyte Inc.

Eusa Pharma

GE Healthcare

Guerbet Group

Hovione FarmaCiencia SA

Imcor Pharmaceutical Co.

Immunomedics Inc.

Insight Agents GmbH

King Pharmaceuticals Inc.

Luna nanoWorks

Macrocyclics

MDS Nordion

NanoScan Imaging

Palatin Technologies Inc.

Pharmacyclics

Point Biomedical Corp.

Starpharma Holdings Ltd.

VisEn Medical Inc.

LIST OF EXHIBITS
 

1.0 EXECUTIVE SUMMARY

Exhibit 1: World Market for X-Ray Medical Contrast Media , 2008-2012

Exhibit 2: World Market for CT Medical Contrast Media 2008-2012

Exhibit 3: World Market for Ultrasound Medical Contrast Media , 2008-2012

Exhibit 4: World Market for MRI Medical Contrast Media 2008-2012

Exhibit 5: World Market for PET Radiopharmaceuticals, 2008-2012

Exhibit 6: World Market for SPECT Radiopharmaceuticals , 2008-2012
 

2.0 INTRODUCTION

Exhibit 7: Key Medical Contrast Agents by Type

Exhibit 8: Advantages of Non-Ionic Contrast Media
 

4.0 MARKETS

Exhibit 10: World Market for Medical Contrast Media and Radiopharmaceuticals, 2007-2012

Exhibit 11: World Market Share for Medical Contrast Media and Radiopharmaceuticals, 2009

Exhibit 12: World Market Share for Medical Contrast Media and Radiopharmaceuticals, 2012

Exhibit 13: Key Players’ Percentage Share - Worldwide Medical Contrast Media Market

Exhibit 14: World Market Geographic Segmentation for Medical X-Ray Procedures, 2008

Exhibit 15: World Market Geographic Segmentation for Medical X-Ray Procedures, 2008

Exhibit 16: Worldwide Medical MRI Procedures, 2008

Exhibit 17: World Market Geographic Segmentation for Medical MRI Procedures, 2008

Exhibit 18: Worldwide Medical CT Procedures, 2008

Exhibit 19: World Market Geographic Segmentation for Medical CT Procedures, 2008

Exhibit 20: Worldwide Medical Ultrasound Procedures, 2008

Exhibit 21: World Market Geographic Segmentation for Medical Ultrasound Procedures, 2008

Exhibit 22: Worldwide Medical PET Procedures, 2008

Exhibit 23: World Market Geographic Segmentation for Medical PET Procedures

Exhibit 24: Status of Selected Medical Imaging Agents

Exhibit 25: World Market for X-Ray Contrast Media, 2007-2012

Exhibit 26: World Market for Medical X-Ray Contrast Media by Geographic Segment 2007-2012

Exhibit 27: World Market for Medical X-Ray Contrast Media by Geographic Segment, 2008

Exhibit 28: World Market for Medical CT Contrast Media, 2007-2012

Exhibit 29: World Market for Medical CT Contrast Media by Geographic Segment, 2007-2012

Exhibit 30: World Market for Medical CT Contrast Media by Geographic Segment, 2008

Exhibit 31: World Market for Medical Ultrasound Contrast Media, 2007-2012

Exhibit 32: World Market for Medical Ultrasound Contrast Media by Geographic Segment, 2007-2012

Exhibit 33: World Market for Medical Ultrasound Contrast Media by Geographic Segment, 2008

Exhibit 34: World Market for Medical MRI Contrast Media, 2007-2012

Exhibit 35: World Market for Medical MRI Contrast Media by Geographic Segment, 2007-2012

Exhibit 36: World Market for Medical MRI Contrast Media by Geographic Segment, 2008

Exhibit 37: Selected Molecular Imaging Products

Exhibit 38: World Market for Medical PET Radiopharmaceuticals, 2007-2012

Exhibit 39: World Market for Medical PET Radiopharmaceuticals by Geographic Segment, 2007-2012

Exhibit 40: World Market for Medical PET Radiopharmaceuticals by Geographic Segment, 2008

Exhibit 41: World Market for Medical SPECT Radiopharmaceuticals, 2007-2012

Exhibit 42: World Market for Medical SPECT Radiopharmaceuticals by Geographic Segment, 2007-2012

Exhibit 43: World Market for Medical SPECT Radiopharmaceuticals by Geographic Segment, 2008